For research purposes only — These compounds aren't FDA approved. All data presented is from clinical trials for educational reference.
PT-141
Blood Flow Peptide
Dosage
Quantity
Price
$26.99
Free shipping on orders $150+
60-day money-back guarantee
Secure checkout
Made in the USA
Certificate of Analysis
Batch verified lab data
99.93%
Purity
- Variant
- PT-141 10mg
- Lot #
- A0112
- Labeled
- 20mg
- Actual
- 22.56mg
- Tested
- Feb 4, 2026
Frequently Researched Together
View allResearch Purposes Snapshot
PT-141 is the investigational name for bremelanotide, an MC4-receptor agonist. The FDA approved an injectable formulation as Vyleesi (June 2019) for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This summary references that development program—your catalog SKU may not be the licensed drug and is not described here as a substitute for prescribing information.
FDA
Regulatory status
Approved June 21, 2019 as Vyleesi (bremelanotide) for specified premenopausal HSDD.
1,247
Phase 3 trials
Women enrolled across RECONNECT studies powering the registration program.
+0.35
Desire score
Integrated placebo-adjusted FSFI desire-domain change (approximate effect size from trial summaries).
MC4R
Mechanism
Melanocortin-4 receptor agonism in hypothalamic circuits linked to sexual motivation.
Cyclic
Peptide scaffold
Heptapeptide backbone developed from melanocortin analog work (MT-II lineage in medicinal chemistry).
Brain-based action
Unlike oral PDE5 inhibitors used for erectile hemodynamics, bremelanotide is framed as a CNS-acting melanocortin agonist that modulates hypothalamic pathways involved in sexual desire rather than primarily relaxing penile vasculature.
Key distinction: PDE5 drugs depend on arousal-related nitric-oxide signaling in genital tissues; bremelanotide trials target motivational neurocircuitry—mechanisms and indications differ materially.
What research has shown
Highlights from the Phase 3 program underlying FDA approval
RECONNECT Phase 3 program
1,247
Women randomized in pivotal trials
FSFI desire domain — placebo-adjusted change (approximate published values)
Participants used bremelanotide 1.75 mg subcutaneously on an as-needed basis for up to 24 weeks; both trials met co-primary endpoints for desire and distress vs placebo in label summaries.
See FDA prescribing information and trial publications for exact estimands and CIs.
Regulatory & statistical highlights
- p < 0.001Sexual desire endpoint — both Phase 3 studies per label narrative
- p < 0.005Distress endpoint — integrated analysis
- 2019FDA approval as first CNS-acting pharmacologic for this HSDD niche
Beyond the labeled indication
Mechanistic themes and exploratory research (not indications for this SKU)
CNS-first
Motivation circuits vs isolated hemodynamic focus.
Both sexes
Male ED and desire data exist outside the women-only approval.
As needed
On-demand dosing paradigm in pivotal program.
Non-PDE5
Alternative pathway for PDE5-incomplete responders (research context).
Sexual desire
Hypothalamic melanocortin axis
Registration trials link MC4R stimulation to improved desire scores and reduced bother from low desire.
- Desire domain↑ vs placebo
- Distress↓ vs placebo
- Satisfaction↑ reported
- Frequency↑ variable
Co-primary endpoints met with p < 0.001 for desire in both RECONNECT studies (label summary).
Male sexual function
ED research (non-label)
Early-phase male studies explored erection quality in PDE5-refractory cohorts—illustrative bars only, not Vyleesi indications.
Onset of action
Pharmacodynamic timing
Subcutaneous autoinjector: onset commonly quoted in the 45–60 minute window with peak near ~2 hours and activity up to ~24 hours—refer to official PK/PD sections.
- Onset45–60 min
- Peak~2 h
- DurationUp to ~24 h
- Route (approved)Subcutaneous
Psychogenic response
Central vs peripheral
Narrative reviews contrast melanocortin-driven motivation with pure vasodilator strategies: bremelanotide is positioned upstream at desire generation rather than only augmenting genital blood flow.
CNS — primary site of action
Key advantage: addresses motivational neurobiology implicated in HSDD rather than relying solely on peripheral hemodynamic facilitation.
Side effects observed in trials
Safety themes from FDA-reviewed studies (~3,500 subjects / 43 trials in label docs)
Nausea, flushing, headache, and injection-site reactions dominate AE tables. Hemodynamic shifts (BP ↑, HR ↓) are transient but monitored. Most events were mild to moderate.
Frequently reported AEs
Nausea
MildFlushing
MildInjection site
MildHeadache
MildTransient mean BP increases (~2–3 mmHg class effect in summaries) and HR decreases may occur; typically resolve within hours. Uncontrolled hypertension and high CV risk are label contraindications.
- Monitor BP in at-risk users per prescribing information
- Effects usually wane within ~12 h of dose
Discontinuation
- Bremelanotide arms (Phase 3)~10%
- Placebo~8%
- Attributed to nausea~4%
- Most treatment discontinuations tracked tolerability rather than lack of efficacy.
- Nausea was the leading AE driving premature withdrawal.
- Overall AE severity skews mild–moderate in pivotal datasets.
- Focal hyperpigmentation (including gingiva, breasts) reported—may not fully fade after stopping.
- Facial hyperpigmentation, especially in darker skin phototypes, appears in postmarketing narratives.
- BP monitoring is advised for cardiovascular comorbidity or antihypertensive polypharmacy.
Storage handling reference
Peptide handling
Cold
Follow manufacturer stability (drug vs research).
Reconstitution
Sterile SC prep if applicable.
Light
Protect vials from UV during prep.
Regulatory
Licensed product ≠ research-grade aliquot.
Researcher notes
- FDA approval gives a dense safety dataset—still map any lab use to local IRB / compound sourcing rules.
- ~3,500 subjects across 43 Palatin-sponsored trials is commonly quoted in regulatory summaries.
- Nausea may improve when dosing aligns with fasting guidance in the official label (confirm current text).
- Hyperpigmentation and BP effects are the longest-lasting clinical cautions beyond GI tolerability.
Important Research Notice
Not for human consumption. This product and all products are sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from journals and official publications but should be fact checked. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations and you do not intend to use it for human consumption.